



THE UNIVERSITY *of* EDINBURGH

Edinburgh Research Explorer

Allelic variations of the multidrug resistance gene determine susceptibility and disease behavior in ulcerative colitis

Citation for published version:

Ho, G-T, Nimmo, ER, Tenesa, A, Fennell, J, Drummond, H, Mowat, C, Arnott, ID & Satsangi, J 2005, 'Allelic variations of the multidrug resistance gene determine susceptibility and disease behavior in ulcerative colitis', *Gastroenterology*, vol. 128, no. 2, pp. 288-96.

Link:

[Link to publication record in Edinburgh Research Explorer](#)

Document Version:

Publisher's PDF, also known as Version of record

Published In:

Gastroenterology

Publisher Rights Statement:

© 2005 by the American Gastroenterological Association

General rights

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.



Allelic Variations of the Multidrug Resistance Gene Determine Susceptibility and Disease Behavior in Ulcerative Colitis

GWO-TZER HO,* ELAINE R. NIMMO,* ALBERT TENESA,[†] JANICE FENNEL,* HAZEL DRUMMOND,* CRAIG MOWAT,* IAN D. ARNOTT,* and JACK SATSANGI*

*Gastrointestinal Unit and [†]MRC Human Genetics Unit, Western General Hospital, Edinburgh, Scotland

Background & Aims: The *MDR1* gene encodes P-glycoprotein 170, an efflux transporter that is highly expressed in intestinal epithelial cells. The *MDR1* exonic single nucleotide polymorphisms (SNPs) C3435T and G2677T have been shown to correlate with activity/expression of P-glycoprotein 170. **Methods:** This was a case-control analysis of *MDR1* C3435T and G2677T SNPs in a large well-characterized Scottish white cohort (335 with ulcerative colitis [UC], 268 with Crohn's disease [CD], and 370 healthy controls). We conducted 2-locus haplotype and detailed univariate and multivariate genotypic-phenotypic analyses. **Results:** The *MDR1* 3435 TT genotype (34.6% vs 26.5%; $P = .04$; odds ratio [OR], 1.60; 95% confidence interval [95% CI], 1.04–2.44) and T-allelic frequencies (58.2% vs 52.8%; $P = .02$; OR, 1.28; 95% CI, 1.03–1.58) were significantly higher in patients with UC compared with controls. No association was seen with CD. The association was strongest with extensive UC (TT genotype: 42.4% vs 26.5%; $P = .003$; OR, 2.64; 95% CI, 1.34–4.99; and T allele: 63.9% vs 52.8%; $P = .009$; OR, 1.70; 95% CI, 1.24–2.29), and this was also confirmed on multivariate analysis ($P = .007$). The G2677T SNP was not associated with UC or CD. These 2 SNPs lie in linkage disequilibrium in our population (D' , .8–.9; r^2 , .7–.8). Two-locus haplotypes showed both positive (3435T/G2677T haplotype: $P = .03$; OR, 1.44) and negative (C3435/2677T haplotype: $P = .002$; OR, .35) associations with UC. Homozygotes for the haplotype 3435T/G2677T were significantly increased in UC ($P = .017$; OR, 8.88; 95% CI, 1.10–71.45). **Conclusions:** Allelic variations of the *MDR1* gene determine disease extent as well as susceptibility to UC in the Scottish population. The present data strongly implicate the C3435T SNP, although the 2-locus haplotype data underline the need for further detailed haplotypic studies.

Ulcerative colitis (UC) and Crohn's disease (CD) are common, chronic inflammatory disorders of the intestines characterized by a dysregulated mucosal immune response.¹ Epidemiologic and linkage studies suggest that genetic factors play a significant role in determining susceptibility to inflammatory bowel disease

(IBD).² Genetic linkage analyses, through genome-wide screens, have identified a number of susceptibility loci, revealing the complexity of IBD.

Recent attention has focused on the multidrug resistance 1 (*MDR1*) gene and its product, P-glycoprotein 170, as a potential determinant of susceptibility to IBD.³ P-glycoprotein 170, which functions as an adenosine triphosphate-dependent efflux transporter pump, is highly expressed in the epithelial surfaces of the intestine, biliary ductules, proximal tubules of kidneys, and central nervous system, where it forms the basis of the blood-brain barrier.^{4–6} Interindividual variability of P-glycoprotein expression in the intestine plays a role in determining the pharmacokinetics of a wide-ranging number of substrates. Nevertheless, the exact physiologic role in the gut remains unknown. The high constitutive levels of expression of P-glycoprotein 170 in the gut suggest a role in protection not only against xenobiotics but also bacterial products.

The *MDR1* gene is an attractive candidate gene for IBD for several reasons.³ First, *mdr-1a*-deficient mice develop a UC-like phenotype when maintained in a specific pathogen-free environment that is reversed with antibiotics.⁷ Bone marrow transfer studies show that these mice develop colitis primarily due to deficiency of *mdr-1* in the epithelial rather than the lymphoid cells. Second, the *MDR1* gene maps to chromosome 7q22, which has been identified as a putative locus of susceptibility for IBD by genome-wide scanning in a UK cohort.⁸ Recent subsequent meta-analysis of all genome-wide scans confirms suggestive linkage to this region.⁹ Most recently, compelling data by Langmann et al have shown that *MDR1* gene expression is down-regulated in IBD with expression significantly reduced in the colonic tissue of patients with UC but not CD.¹⁰ In contrast to

Abbreviations used in this paper: CI, confidence interval; OR, odds ratio; SNP, single nucleotide polymorphism.

© 2005 by the American Gastroenterological Association

0016-5085/05/\$30.00

doi:10.1053/j.gastro.2004.11.019

this, Farrell et al have suggested that increased P-glycoprotein 170 expression may be associated with failure of medical therapy in IBD.¹¹

The *MDR1* gene is composed of 28 exons and is 209 kilobases in length, and 29 single nucleotide polymorphisms (SNPs) have been described.^{12–14} Two SNPs, exonic variant C3435T and G2677T/A, have been shown to correlate with activity/expression of P-glycoprotein 170. The C3435T SNP in exon 26 has been most extensively investigated and was first shown to correlate with expression of P-glycoprotein 170.¹² In this study, the TT genotype was associated with decreased intestinal P-glycoprotein 170 expression with functional consequence as inferred by increased digoxin uptake following oral administration.¹⁵ This has been replicated in other pharmacokinetic studies.^{16–18} In addition, the effect of the *MDR1* C3435T SNP and its postulated correlation with P-glycoprotein 170 activity/expression has been shown to play a role in drug-resistant epilepsy,¹⁹ immune recovery after initiation of antiretroviral therapy in human immunodeficiency virus,²⁰ and the development of renal cell carcinoma.²¹

The G2677T/A SNP in exon 21 results in 2 distinct amino acid changes, namely 893Ser (G2677T) or the much rarer 893Thr (G2677A), and has been shown to be associated with altered transporter function or expression.^{17,22} Several studies have suggested that the C3435T and G2677T SNP may lie in linkage disequilibrium.^{17,23–25}

Recently, Schwab et al in Germany suggested that both T allele and TT genotype were associated with increased susceptibility in UC but not CD.²⁶ Subsequent replication studies involving this SNP alone in other centers have been inconsistent.^{27,28} In a North American study examining both G2677T and C3435T SNPs (and, additionally, a C1236T variant in exon 12), Brant et al²⁹ showed an association only between the Ala893 polymorphism (G2677) and IBD, although these investigators did not specify whether the association was with CD or UC. A significant association was observed from both a case-control study and a pedigree disequilibrium test with IBD. The investigators proposed that the G allele (Ala893) might confer a genetic risk factor to susceptibility of IBD.

We aimed firstly to investigate the contribution of the *MDR1* C3435T and G2677T SNP in a large, independent, well-characterized population of Scottish white people. We determined whether 2-locus haplotypes provide a stronger association with disease than individual SNPs to resolve the controversies regarding the contribution of this gene to disease susceptibility. We rigorously conducted a detailed subphenotypic review of all subjects genotyped to assess whether these variants are

Table 1. Demographics and Clinical Characteristics of Patients With UC (n = 335)

Sex (M/F)	184/151
Age at onset (y)	35.0 (25.3–50.3)
Age at onset younger than 16 years (%)	10 (3)
Smoking history (%)	
Current	28 (8.5)
Ex-smoker	135 (40.4)
Never	172 (51.4)
Ethnicity	
Scottish white (%)	99
Other	1 Jewish, 1 Japanese, and 2 Asian persons
Disease extent	
Extensive disease (beyond the splenic flexure)	118 (35.2)
Left-sided colitis	149 (44.5)
Proctitis	68 (20.3)
Severe disease ^a	113 (33.7)
Surgery for severe disease	63 (18.8)
Extraintestinal manifestations (%)	31 (9.4)
Primary sclerosing cholangitis (%)	6 (1.8)
Azathioprine therapy (%)	48 (14.2)

^aSevere UC defined as patients who developed a severe acute attack of UC satisfying the Truelove and Witts criteria.

particularly implicated in determining disease extent and behavior in IBD. To clarify whether *MDR1* genotypes may influence drug responsiveness in UC, we further subcategorized our patients to the phenotypes of severe disease and need for surgery in UC.

Patients and Methods

Patients

This study was approved by the Lothian Research and Ethics Committee, and written consent was obtained from all patients. A total of 335 patients with UC and 268 with CD were recruited from the Lothian region (Scotland). The diagnosis of IBD was determined by standard clinical, radiologic, endoscopic, and histologic criteria.

Tables 1 and 2 summarize the clinical characteristics of patients studied. The median ages at diagnosis of UC and CD were 35.0 years (interquartile range, 25.3–50.3 years) and 26.6 years (interquartile range, 19.9–37.0 years), respectively. The ethnicity of our study population was predominantly Scottish white (99%). There were more men in the UC cohort (54.5%) than in the CD cohort (43.5%).

Phenotypic Assessment

UC phenotype was classified by disease extent, disease severity, and need for surgery. The extent of disease was documented at the time of latest follow-up. We defined extensive disease as disease extending beyond the splenic flexure, left-sided colitis as disease extending to the splenic flexure, and proctitis as disease limited to the rectum as determined by histologic and macroscopic evidence. In discordant cases, the histologic evidence was used. Patients who had developed an

Table 2. Demographics and Clinical Characteristics of Patients With CD

Sex (M/F)	117/151
Smoking history (%)	
Current	68 (25.4)
Ex-smoker	77 (28.7)
Never	123 (45.9)
Age at onset (y)	26.6
Median (interquartile range)	(19.9–37.0)
Age at onset	203
No. (%) (younger than 40 years, A1)	(75.7)
Ethnicity	
Scottish white (%)	99
Other	(1 Jewish and 2 Asian persons)
Drug therapy (%)	
Infliximab	45 (16.8)
Azathioprine	106 (39.5)
Disease location (%) (n = 240)	
Ileal (L1)	83 (30.9)
Colonic (L2)	118 (39.9)
Ileocolonic (L3)	57 (21.3)
Upper gastrointestinal (L4)	21 (7.9)
Disease behavior at diagnosis (%)	
Inflammatory (B1)	196 (73.1)
Stricturing (B2)	21 (7.8)
Penetrating (B3)	51 (19.0)
Disease behavior at latest follow-up (%)	
Inflammatory (B1)	95 (35.4)
Stricturing (B2)	43 (16.1)
Penetrating (B3)	130 (48.4)
Surgery (%)	122 (45.8)
Extraintestinal manifestations (%)	59 (22.1)

NOTE. Disease location, behavior, and age at onset were defined according to the Vienna classification.

acute severe attack of UC (satisfying the Truelove and Witts criteria) requiring intensive inpatient medical therapy were regarded to have severe UC. Within the category of severe UC, a further subset of patients who had failed to respond to medical therapy and consequently required surgery were categorized under the phenotype “need for surgery.” Other phenotypic details such as smoking, family history, presence of primary sclerosing cholangitis, and other extraintestinal manifestations were also recorded.

CD was classified according to the Vienna classification of disease location, behavior, and age at diagnosis as previously described.³⁰ We have previously shown that disease behavior is not stable over time and therefore have analyzed disease behavior only at time of diagnosis and at latest follow-up.³¹

Controls

A total of 370 healthy controls, comprised of actively recruited healthy subjects (n = 105) and blood donors (n = 265), were all recruited from the Lothian region between 2000 and 2002. There were no differences in the demographics between these 2 groups. There were 179 men and 191 women, and the median age at recruitment was 37.1 years (interquartile range, 25.9–47.0 years).

Genotyping

Genotyping was performed using TaqMan (ABI, San Diego, CA). TaqMan probes were available from ABI-assay-on-demand/design: C3435T (rs1045642) and G2677T/A (rs2032582). Sequence and reaction settings are available on request.

G2677T/A is a triallelic SNP, with reported frequencies of the rare A allele in European white people ranging from undetected to 4%.^{13,17,32–34} We sequenced 200 chromosomes of the UC group (100 individuals) and confirmed a G2677A allelic frequency of only 2% in our population. In view of this low frequency, we chose to genotype the 2 common variants of the G2677T/A SNP using TaqMan reaction.

Data Analysis

Genotype and allelic frequencies between cases and controls were compared using a 2 × 2 table and Fisher exact test. Odds ratios (ORs) are given with 95% confidence intervals (CIs) and 2-sided *P* values. *P* ≤ .05 was considered significant. All calculations were performed using the Graph Pad InStat program (Graph Pad Software, San Diego, CA). Fisher exact test was used to evaluate if the homozygote and heterozygote frequencies for each SNP deviate from the Hardy–Weinberg equilibrium. Two-locus haplotype frequencies were measured using the expectation-maximization algorithm utilizing the SNPHAP program (bioinformatic programs available and accessed via the Medical Research Council–Rosalind Franklind Centre of Genomic Research Web site: <http://www.rfcgr.mrc.ac.uk>).³⁵

Multivariate analysis was performed using a logistic regression model to test the association between phenotype and genotypes. Two methods were used for haplotypic association with disease: (1) the log-likelihood ratio method, in which inferred haplotypes were compared in cases, controls, and cases/controls combined, and (2) directly comparing the haplotype frequencies between cases and controls. The log-likelihood ratio tests whether a model in which haplotype frequencies in cases are different from controls or a model in which there are no differences between cases and controls fit the data obtained better.³⁵ Significance for association was calculated using the test statistic $2 \ln(L_{\text{case}}) + \ln(L_{\text{control}}) - \ln(L_{\text{case/control}})$, which has a χ^2 distribution with $n - 1$ df, where n is the number of inferred haplotypes. We measured the linkage disequilibrium between SNPs using Cocophase software (bioinformatic programs available and accessed via the Medical Research Council–Rosalind Franklind Centre of Genomic Research Web site: <http://www.rfcgr.mrc.ac.uk>).

The log-likelihood analysis and direct haplotype comparison are complementary methods to detect association in haplotypic data sets. Log-likelihood analysis is used specifically to address the problem of phase uncertainty encountered when direct comparisons are made from haplotype frequencies that are inferred. Direct haplotype comparison assumes that all haplotypes are known without error and therefore can be counted. However, there remains a degree of uncertainty even in the

Table 3. Genotype and Allelic Frequencies of *MDR1* C3435T Polymorphism in UC and CD Compared With Controls

	CC (%)	CT (%)	TT (%)	C (%)	T (%)	TT vs CC/OR/95% CI	T vs C/OR/95% CI
UC (n = 335)	61 (18.2)	158 (47.2)	116 (34.6)	280 (41.8)	390 (58.2)	.04/1.60/1.04–2.44	.02/1.28/1.03–1.58
CD (n = 268)	56 (20.9)	140 (52.2)	72 (26.9)	252 (47.0)	284 (53.0)	.81/1.08/.68–1.69	.43/1.03/.83–1.29
Healthy controls (n = 370)	82 (22.2)	190 (51.3)	98 (26.5)	354 (47.8)	386 (52.8)		

NOTE. UC vs CD: TT genotype, $P = .12$; OR, 1.48; 95% CI, .93–2.36; T allele, $P = .07$; OR, 1.24; 95% CI, .98–1.24.

case of estimated diplotypes. Although the likelihood-based method will test for association, it does not provide an estimate of the size of the effect; for this, we used the diplotypes most likely to do so.

Results

Effect of *MDR1* C3435T and G2677T Polymorphism on Overall Disease Susceptibility

Both the T allele and TT genotype of the *MDR1* 3435 SNP were significantly increased in patients with UC (58.2% vs 52.8%; $P = .02$; OR, 1.28; 95% CI, 1.03–1.58) compared with healthy controls (34.6% vs 26.5%; $P = .04$; OR, 1.60; 95% CI, 1.04–2.44) (Table 3). No significant differences in allele or genotype frequencies were seen in patients with CD (53.0% vs 52.8% [$P = .43$] and 26.9% vs 26.5% [$P = .81$], respectively) when compared with controls. A trend toward higher T-allele and genotype frequencies in UC was observed when compared with CD (58.2% vs 53.0% [$P = .12$] and 34.6% vs 26.9% [$P = .07$]).

We did not detect any significant differences in carriage rate (presence of one or 2 copies of alleles) of 3435T in the 3 groups (UC, 81.8%; CD, 79.1%; healthy controls, 77.8%). Our data suggest that the TT genotype rather than T-allele carriage plays the more significant role in the association with UC. The OR, compared with the CC genotype, for the TT genotype was 1.59 (95% CI, 1.04–2.44) and for the CT genotype was 1.12 (95% CI, .76–1.66). Therefore, a stronger significance was also obtained when we compared the homozygosity rate (TT genotype/non-TT genotype) in UC ($P = .02$; OR, 1.47; 95% CI, 1.06–2.03).

No significant differences were observed for allelic and genotype frequencies for *MDR1* G2677T polymorphism

on overall disease susceptibility for either UC or CD (Table 4). There was no overall association with IBD in our population for the G2677T SNP ($P = .26$), although the G2677 allele frequency showed a trend to be higher in patients with UC compared with controls (54.6% and 51.2%, respectively). All genotype frequencies in both cases and controls were consistent with Hardy–Weinberg equilibrium.

In addition to this, we performed a sex-matched analysis for both C3435T and G2677T SNP with controls (335 and 268 healthy controls with 48.5% and 43.5% men for UC and CD, respectively). The association observed with C3435T SNP and UC remained significant, with the TT genotype ($P = .05$; OR, 1.58; 95% CI, 1.02–2.45) and T allele ($P = .03$; OR, 1.26; 95% CI, 1.03–1.06) both significantly increased. No other significant differences were detected in sex-matched analysis (full details available on request).

Linkage Disequilibrium Between C3435T and G2677T Polymorphisms

The C3435T and G2677T SNP are in linkage disequilibrium with each other in our population (cases, $D' = .8$ and $r^2 = .7$; controls, $D' = .9$ and $r^2 = .8$). Therefore, we proceeded to perform 2-locus haplotype association tests with UC and CD.

The Effect of 2-Locus Haplotype (C3435T/G2677T) on Disease Susceptibility

Using the log-likelihood ratio test as described earlier, we were able to show an association of 2-locus haplotypes of C3435T/G2677T with UC ($P = .0056$, 3 *df*). On single haplotype analysis, the carriage of 3435T/2677G haplotype conferred an increased risk for UC (OR, 1.44; $P = .03$; 95% CI, 1.03–1.99) (Table 5). In

Table 4. Genotype and Allele Frequencies of *MDR1* G2677T Polymorphism in UC and CD Compared With Controls

	GG (%)	GT (%)	TT (%)	G (%)	T (%)	GG vs TT/OR/95% CI	G vs T/OR/95% CI
UC (n = 335)	95 (28.3)	176 (52.5)	64 (19.1)	366 (54.6)	304 (45.4)	.16/1.37/.89–2.09	.19/1.15/.93–1.42
CD (n = 268)	75 (27.9)	133 (47.8)	60 (22.4)	283 (52.8)	253 (47.2)	.57/1.15/.74–1.79	.57/1.07/.86–1.34
Healthy controls (n = 370)	102 (27.6)	174 (47.0)	94 (25.4)	378 (51.2)	362 (49.8)		

NOTE. UC vs CD: GG genotype, $P = .48$; OR, 1.19; 95% CI, .75–1.89; G allele, $P = .19$; OR, 1.15; 95% CI, .93–1.89.

Table 5. Two-Locus Haplotypes of C3435T/G2677T SNPs With UC and CD

Haplotype	UC (%)	Healthy Controls (%)	P value/OR/95% CI	CD (%)	Healthy Controls (%)	P value/OR/95% CI
3435T/2677T	291/379 (43.4)	332/408 (44.9)	.59/.94/.76–1.16	219/317 (40.8)	332/408 (44.9)	.16/.85/.67–1.06
C3435/G2677	276/394 (41.2)	300/440 (40.6)	.82/1.03/.83–1.27	221/315 (41.2)	300/440 (40.6)	.82/1.03/.82–1.29
3435T/G2677	91/579 (13.5)	73/667 (9.8)	.03/1.44/1.03–1.99	65/471 (12.1)	73/667 (9.8)	.20/1.26/.88–1.79
C3435/2677T	11/659 (1.7)	34/706 (4.6)	.002/.35/.17–.69	35/501 (5.9)	34/706 (4.6)	.13/1.45/.89–2.36

NOTE. Contingency tests were used to test the association of the inferred haplotypes in the groups of UC and CD, respectively, as compared with the control group (total number of a particular haplotype/total number of remaining haplotypes compared between cases and controls with *P* values and 95% CIs given).

contrast, carriage of the 3435C/2677T haplotype was associated with a protective effect in UC (OR, .35; *P* = .002; 95% CI, .17–.69). Similar trends were observed with the same haplotypes in CD, but these failed to reach significance (3435C/2677T allele, *P* = .20; 3435T/2677G allele, *P* = .13).

It is noteworthy that a significantly higher number of patients with UC were homozygotes for both TT 3435 and GG 2677 compared with a low frequency in healthy controls (8 patients possessing 3435TT and GG 2677 genotype vs 1; *P* = .017; OR, 8.88; 95% CI, 1.10–71.45). A similar trend was observed in patients with CD (5 patients possessing 3435TT and GG 2677 genotype; *P* = .08; OR, 6.82; 95% CI, .79–58.77). Combining UC and CD yielded a greater significance (*P* = .013; OR, 8.34; 95% CI, 1.09–64.07). There were no obvious associations observed in simple and compound heterozygotes of either UC or CD with healthy controls.

Because carriers of double homozygote mutants were uncommon (14 individuals in total), we analyzed the phenotypes of these patients. In UC, 6 of 8 patients had pancolitis, of whom 4 required surgery as a consequence of severe disease. Of the 5 patients with CD carrying these 2 mutations, one patient had colonic disease (L2), 3 had ileocolonic disease (L3), and one had ileal disease (L1); 3 of 5 of these patients required surgery for active disease.

Genotype-Phenotype Analysis: Univariate Analysis

UC and CD. The T allele and TT genotype of the *MDR1* C3435T showed a highly significant association

with the phenotype of extensive disease (OR, 1.70; 95% CI, 1.24–2.29; *P* = .009 and OR, 2.64; 95% CI, 1.34–4.99; *P* = .0027, respectively). Both the frequencies of T allele and TT genotype of *MDR1* C3435T were increased in patients with left-sided colitis and proctitis, but these differences were not significant. A significantly higher T-allele frequency was also observed in patients with severe disease (OR, 1.39; *P* = .04; 95% CI, 1.02–1.88). Although the T-allele and TT-genotype frequencies were even higher in the subgroup of patients who had required surgery for failure of medical treatment for severe UC (T-allele frequency, 60.3%; TT genotype, 41.3%), significance was not achieved in this smaller group (Table 6).

Interestingly, for the *MDR1* G2677T SNP, trends of association to severe disease and surgery were observed for the GG genotype and G allele. In patients with severe disease who required surgery, the GG-genotype frequency was 41.2% compared with 27.5% of controls (*P* = .11; OR, 1.85; 95% CI, .89–3.85). This trend was not observed in the subgroup of patients with extensive disease.

We did not observe any associations with subphenotypic categories of CD (data not shown); specifically, colonic CD was not associated with either SNP (24.7% TT-genotype frequency vs 26.5% for controls; *P* = .9).

Multivariate Analysis

The phenotypes of disease extent, disease severity, and need for surgery were considered in our multivariate model. Multivariate analyses show that the TT genotype of *MDR1* 3435 remained significantly associated with extensive disease (*P* = .007). The phenotypes of severe disease and surgery were not significant (*P* = .8 and *P* =

Table 6. Genotype-Phenotype Analysis for C3435T and G2677T SNP in UC

Genotypes	C3435T						G2677T					
	CC (%)	CT (%)	TT (%)	TT genotype: P value/OR/95% CI	T-allele frequency: P value/OR/95% CI		GG (%)	GT (%)	TT (%)	GG genotype: P value/OR/95% CI	G-allele frequency: P value/OR/95% CI	
Extensive UC	17 (14.4)	51 (43.2)	50 (42.4)	.003/2.64/1.34–4.99	.009/1.70/1.24–2.29		32 (27.1)	60 (50.9)	26 (22.0)	.76/1.13/.63–2.04	.71/1.06/.79–1.42	
Left-sided disease	30 (20.1)	74 (49.7)	45 (30.2)	.49/1.25/.73–2.17	.41/1.12/.86–1.47		44 (29.5)	80 (53.7)	25 (16.8)	.12/1.62/.92–2.85	.13/1.24/.94–1.62	
Proctitis	14 (20.6)	37 (54.4)	21 (30.9)	.58/1.25/.60–2.62	.57/1.11/.79–1.59		19 (27.9)	36 (52.9)	13 (19.1)	.57/1.35/.63–2.88	.51/1.14/.79–1.65	
Severe disease	23 (20.3)	44 (38.9)	46 (40.7)	.09/1.67/.94–2.99	.04/1.39/1.02–1.88		35 (31.0)	53 (47.8)	20 (21.2)	.17/1.61/.87–2.99	.14/1.27/.93–1.72	
Surgery for severe disease	13 (20.6)	24 (38.1)	26 (41.3)	.21/1.67/.81–3.46	.18/1.31/.89–1.91		26 (41.2)	24 (38.1)	13 (20.6)	.11/1.84/.89–3.79	.06/1.46/.99–2.14	

.4, respectively). Other models, which included age at onset, smoking status, presence of primary sclerosing cholangitis, and extraintestinal manifestations, showed no additional associations. No associations were observed with CD.

Discussion

This study firstly provides replicated confirmation for the association of the *MDR1* C3435T SNP with UC. In addition, we have made novel observations with respect to genotype-phenotype correlations, notably the strong association of the C3435T SNP with extensive UC. Finally, the haplotypic analyses involving C3435T and G2677T SNPs provide further new insights into the complexities of the contribution of the *MDR1* gene; both protective and susceptible haplotypes were identified.

Indeed, in view of the strength of the phenotypic associations identified in the present study, it is of interest to reconsider whether the positive association with C3435T SNP seen in the study by Schwab et al²⁶ (43% of patients had extensive UC in that cohort) may have been driven by this phenotype. A significant association with extensive UC was not detected in that study, but that may have been due to lack of statistical power in a smaller subgroup ($n = 63$).

Obvious care has been taken in other studies that have examined these candidate SNPs (C3435T and G2677T/A) by using both case-control and family-based association designs.^{27,29} Croucher et al reported no association of the C3435T SNP with UC or CD in German and British populations.²⁷ In the North American study, in which the C3435T, G2677T/A, and C1236T (exon 12) SNPs were investigated, only the G2677 allele was associated with IBD.²⁹ In that study, Brant et al showed that the G2677 allele (Ala893) was significantly higher in patients with IBD compared with controls (G-allele frequency: 61.5% in UC vs 56.5%; $P = .002$). Significant association was also seen in pedigree disequilibrium transmission only for the subset with CD.

Several factors are pertinent when considering the apparently inconsistent results from these studies. The descriptions of the phenotypic details of the cohorts were lacking, and our data have now emphasized the importance of phenotypic heterogeneity. Parallels may be drawn, in this respect, with the contribution of the *NOD2/CARD15* gene in CD.^{36,37} The number of subjects with UC in the data sets studied was relatively small, and these may have been underpowered to identify a modest contribution. Moreover, the different ethnicity and study populations may confound the overall pic-

ture,³⁸ as also shown by the emerging data regarding *NOD2/CARD15* in European populations.

Our haplotype data provide further insight into the contribution of the *MDR1* gene in determining susceptibility and disease phenotype. By combining the 2 SNPs, the haplotype 3435T/G2677 was shown to confer an increased susceptibility to UC ($P = .03$; OR, 1.44; 95% CI, 1.03–1.99) whereas haplotype C3435/2677T appeared to protect against the development of UC ($P = .002$; OR, .35; 95% CI, .17–.69). The effect was most pronounced in patients who were homozygotes for both *MDR1* 3435 TT and 2677 GG genotype, but we note that the overall number of this group was very low (2.4%). The likelihood ratio for the haplotypic distribution in UC was also significantly different when compared with controls ($P = .0056$). Thus, it appears that these variants can alter the risk for developing UC in a bidirectional fashion. It is particularly interesting that the at-risk haplotype contains allelic variants associated with reduced P-glycoprotein expression in vivo, whereas the alleles on the protective haplotype have been associated with increased expression.

In recent years, the case for the involvement of the *MDR1* gene and P-glycoprotein 170 in determining susceptibility in IBD has become increasingly persuasive. It is clear, however, that the role of the *MDR1* gene/P-glycoprotein 170 in inflammation is likely to be more complex than originally believed. Most pertinently, there seems to be cell, tissue, and even regional organ-specific differences in the regulation of both the function and the expression of P-glycoprotein 170.^{39–43} Increasingly, in vitro and ex vivo studies, including data from our unit involving the HLA-B27 transgenic mice, suggest that P-glycoprotein expression is in fact reduced in the presence of colonic inflammation.^{44–46} This together with the findings by Langmann et al, showing down-regulation of *MDR1* (with other detoxification genes) in colonic tissue of patients with UC, puts forward a compelling argument for an influential role of P-glycoprotein in determining susceptibility to UC.¹⁰ We hypothesize that low levels of P-glycoprotein 170 expression in the gastrointestinal colonic epithelium increases susceptibility and high levels are protective.

Based on our data, the C3435T but not G2677T SNP is primarily associated with UC. This leads to the question whether C3435T is the functional variant or in linkage with another variant. Given that we did not show an association with G2677T alone and that 2-locus haplotypes were not superior in determining risk, we clearly cannot ascribe the significant association seen with C3435T to be secondary to linkage with G2677T/A. The functional effect of the C3435T, a syn-

onymous SNP that does not involve amino acid change, nevertheless remains controversial. It remains possible that this silent SNP can affect P-glycoprotein 170 activity/expression through, for example, effects on messenger RNA stability or codon preference. However, it is pertinent that the correlation between C3435T SNP and P-glycoprotein 170 activity/expression does not seem consistent across ethnic groups. Studies in white populations have shown an association with *MDR1* 3435 TT genotype and decreased P-glycoprotein 170 activity/expression, but the reverse is true for studies involving Japanese populations.^{47–49} Therefore, we propose that the argument that this SNP lies within tight linkage disequilibrium with another unidentified causal variant remains the most plausible explanation. While the hypothetical model suggested by Brant et al, that C3435T lies in linkage disequilibrium with an unknown polymorphism that controls expression and that the G2677T SNP directly affects the innate P-glycoprotein 170 activity, cannot be conclusively disproved, this seems less likely in light of our data.

Does *MDR1* have a role as a pharmacogenetic marker? Farrell et al suggested that high P-glycoprotein 170 expression was associated with failure of medical treatment in IBD.¹¹ The study did not investigate the genetic contribution of the *MDR1* gene. The stratification to severe disease and need for surgery in our study was originally driven by the hypothesis that the CC genotype (in which some studies have shown to be associated with high expression) can predict corticosteroid resistance (severe disease) and therefore surgery. This in fact was clearly shown not to be the case in our study, with the trend being completely reversed (*MDR1* 3435-TT genotype higher in both patients with severe disease and requiring surgery). Recent data from the Oxford data set in abstract form even suggest that the TT genotype of the *MDR1* 3435 SNP may in fact be useful to predict surgery in UC, in conjunction with other genetic markers.⁵⁰

Are allelic variants of the *MDR1* gene implicated in CD? Overall, we detect no significant associations with CD and the subphenotypes according to the Vienna classification of age at onset, disease location, and behavior (data not shown). In particular, no association was seen when we specifically considered only Crohn's colitis with either of the 2 SNPs. We do note, however, trends of associations with 2-locus haplotype (haplotypes 3435T/2677T: OR, .85; $P = .18$; C3435/2677T: OR, 1.39; $P = .19$; and 3435T/G2677: OR, 1.29; $P = .16$). Our CD population is smaller, and given the heterogeneity involved in the presentation of CD, there may be

statistical limitations in conclusively confirming or refuting the hypothesis of association with CD.

In conclusion, our study provides robust evidence to support a role of the *MDR1* gene in the pathogenesis of UC. Germline *MDR1* variation determines both disease susceptibility and course in the Scottish population. The data point to the presence of more than one functional variant or a more haplotype-specific effect and underline the need for parallel functional studies and haplotype analyses.⁵¹

References

- Podolsky DK. Inflammatory bowel disease. *N Engl J Med* 2002; 347:417–429.
- Bonen DK, Cho JH. The genetics of inflammatory bowel disease. *Gastroenterology* 2003;124:521–536.
- Ho GT, Moodie FM, Satsangi J. Multidrug resistance 1 gene (P-glycoprotein 170): an important determinant in gastrointestinal disease? *Gut* 2003;52:759–766.
- Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. *Proc Natl Acad Sci U S A* 1987;84:7735–7738.
- Cordon-Cardo C, O'Brien JP, Casals D, Rittman-Grauer L, Biedler JL, Melamed MR, Bertino JR. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. *Proc Natl Acad Sci U S A* 1989;86:695–698.
- Fojo AT, Ueda K, Slamon DJ, Poplack DG, Gottesman MM, Pastan I. Expression of a multidrug-resistance gene in human tumors and tissues. *Proc Natl Acad Sci U S A* 1987;84:265–269.
- Panwala CM, Jones JC, Viney JL. A novel model of inflammatory bowel disease: mice deficient for the multiple drug resistance gene, *mdr1a*, spontaneously develop colitis. *J Immunol* 1998; 161:5733–5744.
- Satsangi J, Parkes M, Louis E, Hashimoto L, Kato N, Welsh K, Terwilliger JD, Lathrop GM, Bell JI, Jewell DP. Two stage genome-wide search in inflammatory bowel disease provides evidence for susceptibility loci on chromosomes 3, 7 and 12. *Nat Genet* 1996;14:199–202.
- van Heel DA, Fisher SA, Kirby A, Daly MJ, Rioux JD, Lewis CM. Inflammatory bowel disease susceptibility loci defined by genome scan meta-analysis of 1952 affected relative pairs. *Hum Mol Genet* 2004;13:763–770.
- Langmann T, Moehle C, Mauerer R, Scharl M, Liebisch G, Zahn A, Stremmel W, Schmitz G. Loss of detoxification in inflammatory bowel disease: dysregulation of pregnane X receptor target genes. *Gastroenterology* 2004;127:26–40.
- Farrell RJ, Murphy A, Long A, Donnelly S, Cherikuri A, O'Toole D, Mahmud N, Keeling PW, Weir DG, Kelleher D. High multidrug resistance (P-glycoprotein 170) expression in inflammatory bowel disease patients who fail medical therapy. *Gastroenterology* 2000;118:279–288.
- Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, John A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M, Brinkmann U. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. *Proc Natl Acad Sci U S A* 2000;97:3473–3478.
- Cascorbi I, Gerloff T, John A, Meisel C, Hoffmeyer S, Schwab M, Schaeffeler E, Eichelbaum M, Brinkmann U, Roots I. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter *MDR1* gene in white subjects. *Clin Pharmacol Ther* 2001; 69:169–174.

14. Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV, Schwarz UI, Taylor A, Xie HG, McKinsey J, Zhou S, Lan LB, Schuetz JD, Schuetz EG, Wilkinson GR. Identification of functionally variant *MDR1* alleles among European Americans and African Americans. *Clin Pharmacol Ther* 2001;70:189–199.
15. Cascorbi I, Gerloff T, John A, Meisel C, Hoffmeyer S, Schwab M, Schaeffeler E, Eichelbaum M, Brinkmann U, Roots I. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter *MDR1* gene in white subjects. *Clin Pharmacol Ther* 2001;69:169–174.
16. Hitzl M, Drescher S, van der Kuip H, Schaffeler E, Fischer J, Schwab M, Eichelbaum M, Fromm MF. The C3435T mutation in the human *MDR1* gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells. *Pharmacogenetics* 2001;11:293–298.
17. Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV, Schwarz UI, Taylor A, Xie HG, McKinsey J, Zhou S, Lan LB, Schuetz JD, Schuetz EG, Wilkinson GR. Identification of functionally variant *MDR1* alleles among European Americans and African Americans. *Clin Pharmacol Ther* 2001;70:189–199.
18. John A, Kopke K, Gerloff T, Mai I, Rietbrock S, Meisel C, Hoffmeyer S, Kerb R, Fromm MF, Brinkmann U, Eichelbaum M, Brockmoller J, Cascorbi I, Roots I. Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein *MDR1* gene. *Clin Pharmacol Ther* 2002;72:584–594.
19. Siddiqui A, Kerb R, Weale ME, Brinkmann U, Smith A, Goldstein DB, Wood NW, Sisodiya SM. Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene *ABCB1*. *N Engl J Med* 2003;348:1442–1448.
20. Fellay J, Marzolini C, Meaden ER, Back DJ, Buclin T, Chave JP, Decosterd LA, Furrer H, Opravil M, Pantaleo G, Retelska D, Ruiz L, Schinkel AH, Vernazza P, Eap CB, Telenti A. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. *Lancet* 2002;359:30–36.
21. Siegsmond M, Brinkmann U, Schaffeler E, Weirich G, Schwab M, Eichelbaum M, Fritz P, Burk O, Decker J, Alken P, Rothenpieler U, Kerb R, Hoffmeyer S, Brauch H. Association of the P-glycoprotein transporter *MDR1*(C3435T) polymorphism with the susceptibility to renal epithelial tumors. *J Am Soc Nephrol* 2002;13:1847–1854.
22. Tanabe M, Ieiri I, Nagata N, Inoue K, Ito S, Kanamori Y, Takahashi M, Kurata Y, Kigawa J, Higuchi S, Terakawa N, Otsubo K. Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (*MDR*)-1 gene. *J Pharmacol Exp Ther* 2001;297:1137–1143.
23. John A, Kopke K, Gerloff T, Mai I, Rietbrock S, Meisel C, Hoffmeyer S, Kerb R, Fromm MF, Brinkmann U, Eichelbaum M, Brockmoller J, Cascorbi I, Roots I. Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein *MDR1* gene. *Clin Pharmacol Ther* 2002;72:584–594.
24. Zheng H, Webber S, Zeevi A, Schuetz E, Zhang J, Lamba J, Bowman P, Burckart GJ. The *MDR1* polymorphisms at exons 21 and 26 predict steroid weaning in pediatric heart transplant patients. *Hum Immunol* 2002;63:765–770.
25. Horinouchi M, Sakaeda T, Nakamura T, Morita Y, Tamura T, Aoyama N, Kasuga M, Okumura K. Significant genetic linkage of *MDR1* polymorphisms at positions 3435 and 2677: functional relevance to pharmacokinetics of digoxin. *Pharm Res* 2002;19:1581–1585.
26. Schwab M, Schaeffeler E, Marx C, Fromm MF, Kaskas B, Metzler J, Stange E, Herfarth H, Schoelmerich J, Gregor M, Walker S, Cascorbi I, Roots I, Brinkmann U, Zanger UM, Eichelbaum M. An association between the C3435T *MDR1* gene polymorphism and susceptibility for UC. *Gastroenterology* 2003;124:26–33.
27. Croucher PJ, Mascheretti S, Foelsch UR, Hampe J, Schreiber S. Lack of association between the C3435T *MDR1* gene polymorphism and inflammatory bowel disease in two independent Northern European populations. *Gastroenterology* 2003;125:1919–1920.
28. Glas J, Torok HP, Schiemann U, Folwaczny C. *MDR1* gene polymorphism in ulcerative colitis. *Gastroenterology* 2004;126:367.
29. Brant SR, Panhuysen CI, Nicolae D, Reddy DM, Bonen DK, Karaliukas R, Zhang L, Swanson E, Datta LW, Moran T, Ravenhill G, Duerr RH, Achkar JP, Karban AS, Cho JH. *MDR1* Ala893 polymorphism is associated with inflammatory bowel disease. *Am J Hum Genet* 2003;73:1282–1292.
30. Gasche C, Scholmerich J, Brynskov J, D'Haens G, Hanauer SB, Irvine EJ, Jewell DP, Rachmilewitz D, Sachar DB, Sandborn WJ, Sutherland LR. A simple classification of Crohn's disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998. *Inflamm Bowel Dis* 2000;6:8–15.
31. Smith BR, Arnott ID, Drummond HE, Nimmo ER, Satsangi J. Disease location, anti-Saccharomyces cerevisiae antibody, and *NOD2/CARD15* genotype influence the progression of disease behavior in Crohn's disease. *Inflamm Bowel Dis* 2004;10:521–528.
32. Furuno T, Landi MT, Ceroni M, Caporaso N, Bernucci I, Nappi G, Martignoni E, Schaeffeler E, Eichelbaum M, Schwab M, Zanger UM. Expression polymorphism of the blood-brain barrier component P-glycoprotein (*MDR1*) in relation to Parkinson's disease. *Pharmacogenetics* 2002;12:529–534.
33. Gaikovitch EA, Cascorbi I, Mrozikiewicz PM, Brockmoller J, Frotschl R, Kopke K, Gerloff T, Chernov JN, Roots I. Polymorphisms of drug-metabolizing enzymes *CYP2C9*, *CYP2C19*, *CYP2D6*, *CYP1A1*, *NAT2* and of P-glycoprotein in a Russian population. *Eur J Clin Pharmacol* 2003;59:303–312.
34. Gerloff T, Schaefer M, John A, Oselin K, Meisel C, Cascorbi I, Roots I. *MDR1* genotypes do not influence the absorption of a single oral dose of 1 mg digoxin in healthy white males. *Br J Clin Pharmacol* 2002;54:610–616.
35. Zhao JH, Curtis D, Sham PC. Model-free analysis and permutation tests for allelic associations. *Hum Hered* 2000;50:133–139.
36. Ahmad T, Armuzzi A, Bunce M, Mulcahy-Hawes K, Marshall SE, Orchard TR, Crawshaw J, Large O, de Silva A, Cook JT, Barnardo M, Cullen S, Welsh KI, Jewell DP. The molecular classification of the clinical manifestations of Crohn's disease. *Gastroenterology* 2002;122:854–866.
37. Cuthbert AP, Fisher SA, Mirza MM, King K, Hampe J, Croucher PJ, Mascheretti S, Sanderson J, Forbes A, Mansfield J, Schreiber S, Lewis CM, Mathew CG. The contribution of *NOD2* gene mutations to the risk and site of disease in inflammatory bowel disease. *Gastroenterology* 2002;122:867–874.
38. Arnott ID, Nimmo ER, Drummond HE, Fennell J, Smith BR, Morecroft E, MacKinlay J, Anderson N, Kelleher D, O'Sullivan M, McManus R, Satsangi J. *NOD2/CARD15*, *TLR4* and *CD14* mutations in Scottish and Irish Crohn's disease patients: evidence for genetic heterogeneity within Europe? *Genes Immun* 2004;5:417–425.
39. Yacyshyn B, Maksymowych W, Bowen-Yacyshyn MB. Differences in P-glycoprotein-170 expression and activity between Crohn's disease and ulcerative colitis. *Hum Immunol* 1999;60:677–687.
40. Lin JH, Chiba M, Chen IW, Nishime JA, deLuna FA, Yamazaki M, Lin YJ. Effect of dexamethasone on the intestinal first-pass metabolism of indinavir in rats: evidence of cytochrome P-450 3A [correction of P-450 A] and p-glycoprotein induction. *Drug Metab Dispos* 1999;27:1187–1193.
41. Zhao JY, Ikeguchi M, Eckersberg T, Kuo MT. Modulation of multidrug resistance gene expression by dexamethasone in cultured hepatoma cells. *Endocrinology* 1993;133:521–528.
42. Murakami T, Yumoto R, Nagai J, Takano M. Factors affecting the expression and function of P-glycoprotein in rats: drug treatments and diseased states. *Pharmazie* 2002;57:102–107.

43. Moodie FM, Noble J, Satsangi J, Seckl J. Glucocorticoid access and action in the rat colon: expression and regulation of multidrug resistance 1a gene (*mdr1a*), glucocorticoid receptor (GR), mineralocorticoid receptor (MR) and 11-beta-hydroxysteroid dehydrogenase type 2 (11BHDS2) (abstr). *Gut* 2003;A54.
44. Moodie FM, Lyons V, Satsangi J, Seckl J. Effects of glucocorticoids on expression of P-glycoprotein and Glucocorticoid receptor in the intestinal epithelium (abstr). *Gastroenterology* 2004;126:M1136.
45. Mizoguchi E, Xavier RJ, Reinecker HC, Uchino H, Bhan AK, Podolsky DK, Mizoguchi A. Colonic epithelial functional phenotype varies with type and phase of experimental colitis. *Gastroenterology* 2003;125:148–161.
46. Iizasa H, Genda N, Kitano T, Tomita M, Nishihara K, Hayashi M, Nakamura K, Kobayashi S, Nakashima E. Altered expression and function of P-glycoprotein in dextran sodium sulfate-induced colitis in mice. *J Pharm Sci* 2003;92:569–576.
47. Nakamura T, Sakaeda T, Horinouchi M, Tamura T, Aoyama N, Shirakawa T, Matsuo M, Kasuga M, Okumura K. Effect of the mutation (C3435T) at exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects. *Clin Pharmacol Ther* 2002;71:297–303.
48. Drescher S, Schaeffeler E, Hitzl M, Hofmann U, Schwab M, Brinkmann U, Eichelbaum M, Fromm MF. MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine. *Br J Clin Pharmacol* 2002;53:526–534.
49. Sakaeda T, Nakamura T, Horinouchi M, Kakumoto M, Ohmoto N, Sakai T, Morita Y, Tamura T, Aoyama N, Hirai M, Kasuga M, Okumura K. MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects. *Pharm Res* 2001;18:1400–1404.
50. McGovern D, Ahmad T, Van Heel D, Jewell D. A genetic panel strongly predicts the need for colectomy in ulcerative colitis (abstr). *Gastroenterology* 2004;126:A525.
51. Soranzo N, Cavalleri GL, Weale ME, Wood NW, Depondt C, Marguerie R, Sisodiya SM, Goldstein DB. Identifying candidate causal variants responsible for altered activity of the ABCB1 multidrug resistance gene. *Genome Res* 2004;14:1333–1344.

Received August 9, 2004. Accepted November 4, 2004.

Address requests for reprints to: Gwo-Tzer Ho, MBChB, Gastrointestinal Unit, Western General Hospital, Edinburgh, EH4 2XU Scotland. e-mail: gho@ed.ac.uk; fax: (0131) 537 1007.

G.-T.H. is supported by the Chief Scientist Office, Scottish Executive, United Kingdom, and E.R.N. and H.D. are supported by the Wellcome Trust, United Kingdom.

The authors thank Professor Robin Prescott (Medical Statistics Unit, University of Edinburgh, Edinburgh, Scotland) for statistical advice.